For: | Takebayashi K, Inukai T. Effect of proton pump inhibitors on glycemic control in patients with diabetes. World J Diabetes 2015; 6(10): 1122-1131 [PMID: 26322158 DOI: 10.4239/wjd.v6.i10.1122] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v6/i10/1122.htm |
Number | Citing Articles |
1 |
Adriana Sánchez-García, Mario Simental-Mendía, Luis E. Simental-Mendía. Effect of Proton-Pump Inhibitors on Glucose and Insulin Metabolism on Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Pharmaceutical Design 2020; 26(32): 4007 doi: 10.2174/1381612826666200523170718
|
2 |
Shimin Zheng, Juan Ma. A Systematic Review of Gastrointestinal Manifestations in Diabetic Nephropathy. Exploratory Research and Hypothesis in Medicine 2019; 0(000): 1 doi: 10.14218/ERHM.2019.00014
|
3 |
Aline Alberti Morgado, Lilian Rose Marques de Sá, Maria Claudia Araripe Sucupira. Abomasal ulcers: Do ranitidine or omeprazole prevent phenylbutazone-induced lesions in sheep?. Small Ruminant Research 2022; 216: 106782 doi: 10.1016/j.smallrumres.2022.106782
|
4 |
Megumi Shiomi, Tesshu Takada, Yoichi Tanaka, Keiko Yajima, Akira Isomoto, Masaki Sakamoto, Katsuya Otori. Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon‐like peptide‐1 receptor agonists. Journal of Diabetes Investigation 2019; 10(2): 408 doi: 10.1111/jdi.12900
|
5 |
Yusuf Bozkuş, Umut Mousa, Özlem T. İyidir, Nazlı Kırnap, Canan Ç. Demir, Aslı Nar, Neslihan B. Tütüncü. Short-Term Effect of Hypergastrinemia Following Esomeprazole Treatment On Well-Controlled Type 2 Diabetes Mellitus: A Prospective Study. Endocrine, Metabolic & Immune Disorders - Drug Targets 2020; 20(7): 1090 doi: 10.2174/1871530320666200129124555
|
6 |
André J. Scheen. Investigational insulin secretagogues for type 2 diabetes. Expert Opinion on Investigational Drugs 2016; 25(4): 405 doi: 10.1517/13543784.2016.1152260
|
7 |
Timothy M E Davis, Jocelyn Drinkwater, Wendy A Davis. Proton Pump Inhibitors, Nephropathy, and Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study. The Journal of Clinical Endocrinology & Metabolism 2017; 102(8): 2985 doi: 10.1210/jc.2017-00354
|
8 |
Bharat Saboo, Nimmi Mulwani, Anup U Petare, Krishna C Veligandla, Colette S Pinto, Amey Mane, Rahul Rathod, Bhavesh Kotak. An Evidence-Based Retrospective Study for the Management of Acid Peptic Disease With Omeprazole, a Proton Pump Inhibitor, in Indian Patients With Type 2 Diabetes Mellitus (PRIDE-1). Cureus 2022; doi: 10.7759/cureus.32332
|
9 |
Florence Leroux, Damien Bosc, Terence Beghyn, Paul Hermant, Sandrine Warenghem, Valérie Landry, Virginie Pottiez, Valentin Guillaume, Julie Charton, Adrien Herledan, Sarah Urata, Wenguang Liang, Li Sheng, Wei-Jen Tang, Benoit Deprez, Rebecca Deprez-Poulain. Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. European Journal of Medicinal Chemistry 2019; 179: 557 doi: 10.1016/j.ejmech.2019.06.057
|
10 |
Lina A. Dahabiyeh, Eman Y. Abu-rish, Mutasem O. Taha. Inhibition of monoglyceride lipase by proton pump inhibitors: investigation using docking and in vitro experiments. Pharmacological Reports 2020; 72(2): 435 doi: 10.1007/s43440-019-00013-0
|
11 |
Natsuki Eguchi, Arvin John Toribio, Michael Alexander, Ivana Xu, David Lee Whaley, Luis F. Hernandez, Donald Dafoe, Hirohito Ichii. Dysregulation of β-Cell Proliferation in Diabetes: Possibilities of Combination Therapy in the Development of a Comprehensive Treatment. Biomedicines 2022; 10(2): 472 doi: 10.3390/biomedicines10020472
|
12 |
Saruar Alam, Md. Kamrul Hasan, Sharif Neaz, Nazmul Hussain, Md. Faruk Hossain, Tania Rahman. Diabetes Mellitus: Insights from Epidemiology, Biochemistry, Risk Factors, Diagnosis, Complications and Comprehensive Management. Diabetology 2021; 2(2): 36 doi: 10.3390/diabetology2020004
|
13 |
Einas H. Alkhatib, Jody B. Grundman, Anna M. Adamusiak, Melena D. Bellin, Joel P. Brooks, Kevin S. Buckley, Erin M. Janssen, Maleewan Kitcharoensakkul, Kyle P. McNerney, Thea L. Pfeifer, Brooke I. Polk, Brynn E. Marks. Case Report: Insulin hypersensitivity in youth with type 1 diabetes. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1226231
|
14 |
Li-Yuan Yu, Lu-Ning Sun, Xue-Hui Zhang, Yue-Qi Li, Lei Yu, Zi-Qing-Yun Yuan, Ling Meng, Hong-Wen Zhang, Yong-Qing Wang. A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors. Advances in Therapy 2017; 34(5): 1070 doi: 10.1007/s12325-017-0532-9
|
15 |
Jarin Tasnim, Najihah Mohd Hashim, Heh Choon Han. A comprehensive review on potential drug–drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP‐4 inhibitors. Cell Biochemistry and Function 2024; 42(2) doi: 10.1002/cbf.3967
|
16 |
Eman Abdullah, Sarraa Dhiaa, Khalaf Saleh, Marwan Merkhan. Effect of esomeprazole on lipid profile in patients with peptic ulcer. Pharmacia 2021; 68(3): 613 doi: 10.3897/pharmacia.68.e70292
|
17 |
Krister Bokvist, Ying Ding, William H. Landschulz, Vikram Sinha, Aleksandra Pastrak, Ruth M. Belin. Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues. Diabetes, Obesity and Metabolism 2019; 21(7): 1606 doi: 10.1111/dom.13695
|
18 |
Kelly Villegas, Joy L. Meier, Maureen Long, Julio Lopez, Arthur Swislocki. The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes. Metabolic Syndrome and Related Disorders 2019; 17(4): 192 doi: 10.1089/met.2018.0138
|
19 |
Carol Chiung-Hui Peng, Yu-Kang Tu, Gin Yi Lee, Rachel Huai-En Chang, Yuting Huang, Khulood Bukhari, Yao-Chou Tsai, Yunting Fu, Huei-Kai Huang, Kashif M Munir. Effects of Proton Pump Inhibitors on Glycemic Control and Incident Diabetes: A Systematic Review and Meta-analysis. The Journal of Clinical Endocrinology & Metabolism 2021; 106(11): 3354 doi: 10.1210/clinem/dgab353
|